AKT/NF‐κB inhibitor xanthohumol targets cell growth and angiogenesis in hematologic malignancies
Open Access
- 18 October 2007
- Vol. 110 (9), 2007-2011
- https://doi.org/10.1002/cncr.23017
Abstract
BACKGROUND. Leukemias are dependent on Akt/NF‐κB activation and angiogenesis. METHODS. The antiangiogenic Akt/NF‐κB inhibitor xanthohumol (XN) has in vitro activity against acute and chronic myelogenous leukemia cell lines (AML, CML) and fresh samples from patients were investigated. RESULTS. Inhibition of cell proliferation is associated with induction of apoptosis and reduced VEGF secretion. Decreased cell invasion, metalloprotease production, and adhesion to endothelial cells observed in the presence of XN could prevent in vivo life‐threatening complications of leukostasis and tissue infiltration. CONCLUSIONS. As endothelial cells and hematopoietic cells are mutually correlated in their development and growth, targeting both tumor cells and endothelial cells with agents possessing cytotoxic and antiangiogenic activities may lead to synergistic antitumor effects interrupting a reciprocal stimulatory loop between leukemia and endothelial cells. Cancer 2007. © 2007 American Cancer Society.Keywords
This publication has 18 references indexed in Scilit:
- Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemiaBlood, 2006
- Targeting NF-κB in hematologic malignanciesCell Death & Differentiation, 2006
- Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF‐κB and Akt as targetsThe FASEB Journal, 2005
- Bcr-Abl Expression Levels Determine the Rate of Development of Resistance to Imatinib Mesylate in Chronic Myeloid LeukemiaCancer Research, 2005
- Xanthohumol kills B-chronic lymphocytic leukemia cells by an apoptotic mechanismMolecular Nutrition & Food Research, 2005
- Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cellsBlood, 2005
- Essential role for the p110 isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemiaBlood, 2005
- Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatmentBlood, 2003
- A non-isotopic, highly sensitive, fluorimetric, cell-cell adhesion microplate assay using calcein AM-labeled lymphocytesJournal of Immunological Methods, 1995
- Modulation of CD13 expression during retinoic acid-induced differentiation of HL60 cellsLeukemia Research, 1994